FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2968358239> ?p ?o ?g. }

• W2968358239 endingPage "8" @default.
• W2968358239 startingPage "1" @default.
• W2968358239 abstract "Lentiviral vectors (LVs) are excellent tools for gene transfer into mammalian cells. It is noteworthy that the first gene therapy treatment using LVs was approved for commercialization in 2017. The G glycoprotein from rhabdovirus vesicular stomatitis virus (VSV-G) is the glycoprotein most used to pseudotype LVs, due to its high efficiency in transducing several cell types and its resistance to viral vector purification and storage conditions. However, VSV-G expression induces cytotoxicity, which limits LV production to short periods. As alternative to VSV-G, γ-retrovirus glycoproteins (4070A derived, GaLV derived, and RD114 derived) have been used to pseudotype both γ-retroviral vectors (RVs) and LVs. These glycoproteins do not induce cytotoxicity, allowing the development of stable LV producer cells. Additionally, these LV pseudotypes present higher transduction efficiencies of hematopoietic stem cells when compared to VSV-G. Here, new 4070A-, RD114-TR-, and GaLV-TR-derived glycoproteins were developed with the aim of improving its cytoplasmic tail R-peptide cleavage and thus increase LV infectious titers. The new glycoproteins were tested in transient LV production using the wild-type or the less active T26S HIV-1 protease. The GaLV-TR-derived glycoproteins were able to overcome titer differences observed between LV production using wild-type and T26S protease. Additionally, these glycoproteins were even able to increase LV titers, evidencing its potential as an alternative glycoprotein to pseudotype LVs. Lentiviral vectors (LVs) are excellent tools for gene transfer into mammalian cells. It is noteworthy that the first gene therapy treatment using LVs was approved for commercialization in 2017. The G glycoprotein from rhabdovirus vesicular stomatitis virus (VSV-G) is the glycoprotein most used to pseudotype LVs, due to its high efficiency in transducing several cell types and its resistance to viral vector purification and storage conditions. However, VSV-G expression induces cytotoxicity, which limits LV production to short periods. As alternative to VSV-G, γ-retrovirus glycoproteins (4070A derived, GaLV derived, and RD114 derived) have been used to pseudotype both γ-retroviral vectors (RVs) and LVs. These glycoproteins do not induce cytotoxicity, allowing the development of stable LV producer cells. Additionally, these LV pseudotypes present higher transduction efficiencies of hematopoietic stem cells when compared to VSV-G. Here, new 4070A-, RD114-TR-, and GaLV-TR-derived glycoproteins were developed with the aim of improving its cytoplasmic tail R-peptide cleavage and thus increase LV infectious titers. The new glycoproteins were tested in transient LV production using the wild-type or the less active T26S HIV-1 protease. The GaLV-TR-derived glycoproteins were able to overcome titer differences observed between LV production using wild-type and T26S protease. Additionally, these glycoproteins were even able to increase LV titers, evidencing its potential as an alternative glycoprotein to pseudotype LVs." @default.
• W2968358239 created "2019-08-22" @default.
• W2968358239 creator A5004522658 @default.
• W2968358239 creator A5021060711 @default.
• W2968358239 creator A5032090101 @default.
• W2968358239 creator A5060480274 @default.
• W2968358239 creator A5062552367 @default.
• W2968358239 creator A5067043910 @default.
• W2968358239 date "2019-12-01" @default.
• W2968358239 modified "2023-10-01" @default.
• W2968358239 title "Improved GaLV-TR Glycoproteins to Pseudotype Lentiviral Vectors: Impact of Viral Protease Activity in the Production of LV Pseudotypes" @default.
• W2968358239 cites W103437854 @default.
• W2968358239 cites W1505738988 @default.
• W2968358239 cites W1544126343 @default.
• W2968358239 cites W1654570214 @default.
• W2968358239 cites W1837543172 @default.
• W2968358239 cites W1978335031 @default.
• W2968358239 cites W1984042001 @default.
• W2968358239 cites W2005569064 @default.
• W2968358239 cites W2005881075 @default.
• W2968358239 cites W2009761723 @default.
• W2968358239 cites W2017598005 @default.
• W2968358239 cites W2021534641 @default.
• W2968358239 cites W2023016241 @default.
• W2968358239 cites W2024624336 @default.
• W2968358239 cites W2027740034 @default.
• W2968358239 cites W2030866906 @default.
• W2968358239 cites W2035738127 @default.
• W2968358239 cites W2039995391 @default.
• W2968358239 cites W2046456996 @default.
• W2968358239 cites W2054933548 @default.
• W2968358239 cites W2055123567 @default.
• W2968358239 cites W2060106616 @default.
• W2968358239 cites W2062480220 @default.
• W2968358239 cites W2065341945 @default.
• W2968358239 cites W2069519855 @default.
• W2968358239 cites W2070743726 @default.
• W2968358239 cites W2078002493 @default.
• W2968358239 cites W2079000181 @default.
• W2968358239 cites W2080479845 @default.
• W2968358239 cites W2082139926 @default.
• W2968358239 cites W2089579355 @default.
• W2968358239 cites W2093456378 @default.
• W2968358239 cites W2094643993 @default.
• W2968358239 cites W2112936117 @default.
• W2968358239 cites W2112946827 @default.
• W2968358239 cites W2119680107 @default.
• W2968358239 cites W2121894625 @default.
• W2968358239 cites W2135205416 @default.
• W2968358239 cites W2135332827 @default.
• W2968358239 cites W2141322335 @default.
• W2968358239 cites W2154853638 @default.
• W2968358239 cites W2157514015 @default.
• W2968358239 cites W2160031263 @default.
• W2968358239 cites W2166668702 @default.
• W2968358239 cites W2166948779 @default.
• W2968358239 cites W2167958044 @default.
• W2968358239 cites W2169316289 @default.
• W2968358239 cites W2171542740 @default.
• W2968358239 cites W2253012601 @default.
• W2968358239 cites W2285916053 @default.
• W2968358239 cites W2385299939 @default.
• W2968358239 cites W2561666678 @default.
• W2968358239 cites W2761903310 @default.
• W2968358239 cites W2794581912 @default.
• W2968358239 cites W4238350555 @default.
• W2968358239 doi "https://doi.org/10.1016/j.omtm.2019.08.001" @default.
• W2968358239 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6742969" @default.
• W2968358239 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31528654" @default.
• W2968358239 hasPublicationYear "2019" @default.
• W2968358239 type Work @default.
• W2968358239 sameAs 2968358239 @default.
• W2968358239 citedByCount "11" @default.
• W2968358239 countsByYear W29683582392020 @default.
• W2968358239 countsByYear W29683582392021 @default.
• W2968358239 countsByYear W29683582392022 @default.
• W2968358239 crossrefType "journal-article" @default.
• W2968358239 hasAuthorship W2968358239A5004522658 @default.
• W2968358239 hasAuthorship W2968358239A5021060711 @default.
• W2968358239 hasAuthorship W2968358239A5032090101 @default.
• W2968358239 hasAuthorship W2968358239A5060480274 @default.
• W2968358239 hasAuthorship W2968358239A5062552367 @default.
• W2968358239 hasAuthorship W2968358239A5067043910 @default.
• W2968358239 hasBestOaLocation W29683582391 @default.
• W2968358239 hasConcept C104317684 @default.
• W2968358239 hasConcept C108625454 @default.
• W2968358239 hasConcept C111599444 @default.
• W2968358239 hasConcept C114851261 @default.
• W2968358239 hasConcept C133936738 @default.
• W2968358239 hasConcept C15152581 @default.
• W2968358239 hasConcept C153911025 @default.
• W2968358239 hasConcept C159047783 @default.
• W2968358239 hasConcept C2522874641 @default.
• W2968358239 hasConcept C2778431562 @default.
• W2968358239 hasConcept C2778707650 @default.
• W2968358239 hasConcept C2779057330 @default.
• W2968358239 hasConcept C32470452 @default.
• W2968358239 hasConcept C40767141 @default.

• next